# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price tar...
Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day im...
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price tar...
CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.67) b...
Full target enrollment of 216 patients achieved Topline data from CARPO expected in 2Q 2024 LA JOLLA, Calif., April 24, 2024 /P...
The Dow Jones index closed lower by around 400 points on Tuesday. When insiders purchase or sell shares, it indicates their con...
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and maintains $14 price target.